Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) is an endogenous inhibitor of the LDL receptor (LDLR). Mendelian randomization studies suggest that PCSK9 deficiency increases diabetes risk, but the underlying mechanisms remain unknown. The aim of our study was to investigate whether PCSK9 or i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Atherosclerosis 2021-06, Vol.326, p.47-55
Hauptverfasser:	Ramin-Mangata, Stéphane, Thedrez, Aurélie, Nativel, Brice, Diotel, Nicolas, Blanchard, Valentin, Wargny, Matthieu, Aguesse, Audrey, Billon-Crossouard, Stéphanie, Vindis, Cécile, Le May, Cédric, Hulin, Philippe, Armanet, Mathieu, Gmyr, Valery, Pattou, François, Croyal, Mikaël, Meilhac, Olivier, Nobécourt, Estelle, Cariou, Bertrand, Lambert, Gilles
Format:	Artikel
Sprache:	eng
Schlagworte:	Beta cell Cardiology and cardiovascular system Endocrinology and metabolism Human health and pathology Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Hépatology and Gastroenterology Insulin-Secreting Cells LDL receptor Life Sciences PCSK9 PCSK9 inhibitors Proprotein Convertase 9 Receptors, LDL Statins Subtilisins Tissues and Organs
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!